Temporal Trends of Molecular Markers Associated with Artemether-lumefantrine Tolerance/resistance in Bagamoyo District, Tanzania

Overview

Journal Malar J

Publisher Biomed Central

Specialty Tropical Medicine

Date 2013 Mar 20

PMID 23506218

Citations 53

Authors

Maja Malmberg

Billy Ngasala

Pedro E Ferreira

Erik Larsson

Irina Jovel

Angelica Hjalmarsson

Max Petzold

Zul Premji

Jose P Gil

Anders Bjorkman

Andreas Martensson

Affiliations

Soon will be listed here.

Abstract

Background: Development and spread of Plasmodium falciparum resistance to artemisinin-based combination therapy (ACT) constitutes a major threat to recent global malaria control achievements. Surveillance of molecular markers could act as an early warning system of ACT-resistance before clinical treatment failures are apparent. The aim of this study was to analyse temporal trends of established genotypes associated with artemether-lumefantrine tolerance/resistance before and after its deployment as first-line treatment for uncomplicated malaria in Tanzania 2006.

Methods: Single nucleotide polymorphisms in the P. falciparum multidrug resistance gene 1 (pfmdr1) N86Y, Y184F, D1246Y and P. falciparum chloroquine transporter gene (pfcrt) K76T were analysed from dried blood spots collected during six consecutive studies from children with uncomplicated P. falciparum malaria in Fukayosi village, Bagamoyo District, Tanzania, between 2004-2011.

Results: There was a statistically significant yearly increase of pfmdr1 N86, 184F, D1246 and pfcrt K76 between 2006-2011 from 14% to 61% (yearly OR = 1.38 [95% CI 1.25-1.52] p < 0.0001), 14% to 35% (OR = 1.17 [95% CI 1.07-1.30] p = 0.001), 54% to 85% (OR = 1.21 [95% CI 1.03-1.42] p = 0.016) and 49% to 85% (OR = 1.33 [95% CI 1.17-1.51] p < 0.0001), respectively. Unlike for the pfmdr1 SNP, a significant increase of pfcrt K76 was observed already between 2004-2006, from 26% to 49% (OR = 1.68 [95% CI 1.17-2.40] p = 0.005). From 2006 to 2011 the pfmdr1 NFD haplotype increased from 10% to 37% (OR = 1.25 [95% CI 1.12-1.39] p < 0.0001), whereas the YYY haplotype decreased from 31% to 6% (OR = 0.73 [95% CI 0.56-0.98] p = 0.018). All 390 successfully analysed samples had one copy of the pfmdr1 gene.

Conclusion: The temporal selection of molecular markers associated with artemether-lumefantrine tolerance/resistance may represent an early warning sign of impaired future drug efficacy. This calls for stringent surveillance of artemether-lumefantrine efficacy in Tanzania and emphasizes the importance of molecular surveillance as a complement to standard in vivo trials.

Citing Articles

Assessing fitness costs in malaria parasites: a comprehensive review and implications for drug resistance management.

Segovia X, Srivastava B, Serrato-Arroyo S, Guerrero A, Huijben S Malar J. 2025; 24(1):65.

PMID: 40025552 PMC: 11871665. DOI: 10.1186/s12936-025-05286-w.

Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in mainland Tanzania, 2019.

Ngasala B, Chiduo M, Mmbando B, Francis F, Bushukatale S, Makene T Malar J. 2024; 23(1):101.

PMID: 38594679 PMC: 11005286. DOI: 10.1186/s12936-024-04931-0.

Efficacy of artesunate-amodiaquine for treatment of uncomplicated Plasmodium falciparum malaria in mainland Tanzania.

Ngasala B, Bushukatale S, Chiduo M, Makene T, Mkony L, Mohamed A Malar J. 2024; 23(1):90.

PMID: 38553737 PMC: 10979577. DOI: 10.1186/s12936-024-04923-0.

Trends of Plasmodium falciparum molecular markers associated with resistance to artemisinins and reduced susceptibility to lumefantrine in Mainland Tanzania from 2016 to 2021.

Bakari C, Mandara C, Madebe R, Seth M, Ngasala B, Kamugisha E Malar J. 2024; 23(1):71.

PMID: 38461239 PMC: 10924419. DOI: 10.1186/s12936-024-04896-0.

Evolution of Plasmodium falciparum antimalarial drug resistance markers post-adoption of artemisinin-based combination therapies in Yaounde, Cameroon.

Niba P, Nji A, Chedjou J, Hansson H, Hocke E, Ali I Int J Infect Dis. 2023; 132:108-117.

PMID: 37028468 PMC: 10182900. DOI: 10.1016/j.ijid.2023.03.050.

References

Noedl H, Se Y, Schaecher K, Smith B, Socheat D, Fukuda M . Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med. 2008; 359(24):2619-20. DOI: 10.1056/NEJMc0805011. View

Veiga M, Ferreira P, Bjorkman A, Gil J . Multiplex PCR-RFLP methods for pfcrt, pfmdr1 and pfdhfr mutations in Plasmodium falciparum. Mol Cell Probes. 2006; 20(2):100-4. DOI: 10.1016/j.mcp.2005.10.003. View

Holmgren G, Hamrin J, Svard J, Martensson A, Gil J, Bjorkman A . Selection of pfmdr1 mutations after amodiaquine monotherapy and amodiaquine plus artemisinin combination therapy in East Africa. Infect Genet Evol. 2007; 7(5):562-9. DOI: 10.1016/j.meegid.2007.03.005. View

Babiker H, Hastings I, Swedberg G . Impaired fitness of drug-resistant malaria parasites: evidence and implication on drug-deployment policies. Expert Rev Anti Infect Ther. 2009; 7(5):581-93. DOI: 10.1586/eri.09.29. View

Duraisingh M, Jones P, Sambou I, von Seidlein L, Pinder M, Warhurst D . The tyrosine-86 allele of the pfmdr1 gene of Plasmodium falciparum is associated with increased sensitivity to the anti-malarials mefloquine and artemisinin. Mol Biochem Parasitol. 2000; 108(1):13-23. DOI: 10.1016/s0166-6851(00)00201-2. View

Ngasala B, Malmberg M, Carlsson A, Ferreira P, Petzold M, Blessborn D . Efficacy and effectiveness of artemether-lumefantrine after initial and repeated treatment in children <5 years of age with acute uncomplicated Plasmodium falciparum malaria in rural Tanzania: a randomized trial. Clin Infect Dis. 2011; 52(7):873-82. DOI: 10.1093/cid/cir066. View

Sisowath C, Ferreira P, Bustamante L, Dahlstrom S, Martensson A, Bjorkman A . The role of pfmdr1 in Plasmodium falciparum tolerance to artemether-lumefantrine in Africa. Trop Med Int Health. 2007; 12(6):736-42. DOI: 10.1111/j.1365-3156.2007.01843.x. View

Reed M, Saliba K, Caruana S, Kirk K, Cowman A . Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum. Nature. 2000; 403(6772):906-9. DOI: 10.1038/35002615. View

Mangera C, Mbai F, Omedo I, Mireji P, Omar S . Changes in genotypes of Plasmodium falciparum human malaria parasite following withdrawal of chloroquine in Tiwi, Kenya. Acta Trop. 2012; 123(3):202-7. DOI: 10.1016/j.actatropica.2012.05.007. View

10.

Borrmann S, Sasi P, Mwai L, Bashraheil M, Abdallah A, Muriithi S . Declining responsiveness of Plasmodium falciparum infections to artemisinin-based combination treatments on the Kenyan coast. PLoS One. 2011; 6(11):e26005. PMC: 3213089. DOI: 10.1371/journal.pone.0026005. View

11.

Veiga M, Ferreira P, Jornhagen L, Malmberg M, Kone A, Schmidt B . Novel polymorphisms in Plasmodium falciparum ABC transporter genes are associated with major ACT antimalarial drug resistance. PLoS One. 2011; 6(5):e20212. PMC: 3102103. DOI: 10.1371/journal.pone.0020212. View

12.

Martensson A, Ngasala B, Ursing J, Veiga M, Wiklund L, Membi C . Influence of consecutive-day blood sampling on polymerase chain reaction-adjusted parasitological cure rates in an antimalarial-drug trial conducted in Tanzania. J Infect Dis. 2007; 195(4):597-601. DOI: 10.1086/510910. View

13.

Sisowath C, Petersen I, Veiga M, Martensson A, Premji Z, Bjorkman A . In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa. J Infect Dis. 2009; 199(5):750-7. PMC: 2718568. DOI: 10.1086/596738. View

14.

Amaratunga C, Sreng S, Suon S, Phelps E, Stepniewska K, Lim P . Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study. Lancet Infect Dis. 2012; 12(11):851-8. PMC: 3786328. DOI: 10.1016/S1473-3099(12)70181-0. View

15.

Laufer M, Takala-Harrison S, Dzinjalamala F, Stine O, Taylor T, Plowe C . Return of chloroquine-susceptible falciparum malaria in Malawi was a reexpansion of diverse susceptible parasites. J Infect Dis. 2010; 202(5):801-8. PMC: 3380613. DOI: 10.1086/655659. View

16.

Lekana-Douki J, Dinzouna Boutamba S, Zatra R, Zang Edou S, Ekomy H, Bisvigou U . Increased prevalence of the Plasmodium falciparum Pfmdr1 86N genotype among field isolates from Franceville, Gabon after replacement of chloroquine by artemether-lumefantrine and artesunate-mefloquine. Infect Genet Evol. 2011; 11(2):512-7. DOI: 10.1016/j.meegid.2011.01.003. View

17.

Price R, Uhlemann A, Brockman A, McGready R, Ashley E, Phaipun L . Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet. 2004; 364(9432):438-447. PMC: 4337987. DOI: 10.1016/S0140-6736(04)16767-6. View

18.

Raman J, Mauff K, Muianga P, Mussa A, Maharaj R, Barnes K . Five years of antimalarial resistance marker surveillance in Gaza Province, Mozambique, following artemisinin-based combination therapy roll out. PLoS One. 2011; 6(10):e25992. PMC: 3195082. DOI: 10.1371/journal.pone.0025992. View

19.

Dondorp A, Nosten F, Yi P, Das D, Phyo A, Tarning J . Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009; 361(5):455-67. PMC: 3495232. DOI: 10.1056/NEJMoa0808859. View

20.

Mwai L, Kiara S, Abdirahman A, Pole L, Rippert A, Diriye A . In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1. Antimicrob Agents Chemother. 2009; 53(12):5069-73. PMC: 2786317. DOI: 10.1128/AAC.00638-09. View